Inhibition of LPS-induced production of inflammatory factors in the macrophages by mono-carbonyl analogues of curcumin

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3370-3379

  Liang, Guang ^a,b   Zhou, Huiping ^c   Wang, Yi ^a   Gurley, Emily C ^c   Feng, Biao ^a   Chen, Li ^c   Xiao, Jian ^a   Yang, Shulin ^b   Li, Xiaokun ^a,b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Anti inflammatory activity; COX 2; Curcumin analogues; Inflammatory factor; SAR

Indexed keywords

CARBON; CURCUMIN; INTERLEUKIN 6; KETONE; LIPOPOLYSACCHARIDE; MESSENGER RNA; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; CHEMICAL MODEL; CHEMISTRY; CURCUMA; INFLAMMATION; MACROPHAGE; METABOLISM; MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; CARBON; CURCUMA; CURCUMIN; INFLAMMATION; INTERLEUKIN-6; KETONES; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MODELS, CHEMICAL; PLANT EXTRACTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

CURCUMA LONGA;

EID: 76149127226     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00711.x     Document Type: Article

References (37)

1. Papadakis KA, Targan SR. The role of chemokines and chemokine receptors in mucosal inflammation. Inflamm Bowel Dis. 2000, 6:303-13.
2. Popa C, Netea MG, Van Riel PL. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res. 2007, 48:751-62.
3. Newton RC, Decicco CP. Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. J Med Chem. 1999, 42:2295-314.
4. Gautam SC, Gao X, Dulchavsky S. Immunomodulation by curcumin. Adv Exp Med Biol. 2007, 595:321-41.
5. Chan MM. Inhibition of tumor necrosis factor by curcumin, a phytochemical. Biochem Pharmacol. 1995, 49:1551-6.
6. Cho JW, Lee KS, Kim CW. Curcumin attenuates the expression of IL-1beta, IL-6, and TNF-alpha as well as cyclin E in TNF-alpha-treated HaCaT cells; NF-kappaB and MAPKs as potential upstream targets. Int J Mol Med. 2007, 19:469-74.
7. Grandjean-Laquerriere A, Gangloff SC, Le Naour R. Relative contribution of NF-kappaB and AP-1 in the modulation by curcumin and pyrrolidine dithiocarbamate of the UVB-induced cytokine expression by keratinocytes. Cytokine 2002, 18:168-77.
8. Hsu HY, Chu LC, Hua KF. Heme oxygenase-1 mediates the anti-inflammatory effect of curcumin within LPS-stimulated human monocytes. J Cell Physiol. 2008, 215:603-12.
9. Kang BY, Kang BY, Chung SW. Inhibition of interleukin-12 production in lipopolysaccharide-activated macrophages by curcumin. Eur J Pharmacol. 1999, 384:191-5.
10. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp Med Biol. 2007, 595:471-80.
11. Clinical development plan: curcumin. J Cell Biochem. 1996, 26S:72-85. NCI, DCPC
12. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007, 595:453-60.
13. Sharma RA, McLelland HR, Hill KA. Pharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001, 7:1894-900.
14. Dhillon B, Aggarwal BB, Newman RA. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008, 14:4491-9.
15. Rosemond MJ, St John-Williams L, Yamaguchi T. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact. 2004, 147:129-39.
16. Grogan G. Emergent mechanistic diversity of enzyme-catalysed beta-diketone cleavage. Biochem J. 2005, 388:721-30.
17. Liang G, Yang S, Jiang L. Synthesis and anti-bacterial properties of mono-carbonyl analogues of curcumin. Chem Pharm Bull. 2008, 56:162-7.
18. Liang G, Li X, Chen L. Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorg Med Chem Lett. 2008, 18:1525-9.
19. Liang G, Shao L, Wang Y. Exploration and synthesis of curcumin analogues with improved structural stability as anti-tumor agents. Bioorg Med Lett 2008, 10.1016/j.bmc.2008.10.044, doi
20. Dumitru CD, Ceci JD, Tsatsanis C. TNF-a induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway. Cell. 2000, 103:1071-83.
21. Lund S, Christensen KV, Hedtjärn M. The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. J Neuroimmunol. 2006, 180:71-87.
22. Claria J, Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des. 2005, 11:3431-47.
23. Greten FR, Eckmann L, Greten TF. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated, cancer. Cell 2004, 118:285-96.
24. Karin M, Cao Y, Greten FR. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002, 2:301-15.
25. Surh YJ, Chun KS, Cha HH. Molecular mechanisms underlying chemopreventive activities of anti-inflamatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res. 2001, 480:243-68.
26. Pan MH, Lin-Shiau SY, Lin JK. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol. 2000, 60:1665-76.
27. Breinig M, Schirmacher P, Kern MA. Cyclooxygenase-2 (COX-2)-a therapeutic target in liver cancer. Curr Pharm Des. 2007, 13:3305-15.
28. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 2003, 191:125-35.
29. Lin L, Shi Q, Nyarko AK. Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents. J Med Chem. 2006, 49:3963-72.
30. Selvam C, Jachak SM, Thilagavathi R. Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett. 2005, 15:1793-7.
31. Zambre AP, Kulkarni VM, Padhye S. Novel curcumin analogs targeting TNF-induced NF-jB activation and proliferation in human leukemic KBM-5 cells. Bioorg Med Chem. 2006, 14:7196-204.
32. Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J 2006, 8:E443-9.
33. Litwinienko G, Ingold KU. Abnormal solvent effects on hydrogen atom abstraction: resolution of the curcumin antioxidant controversy. The role of sequential proton loss electron transfer. J Org Chem. 2004, 69:5888-96.
34. Barclay LRC, Vinqvist MR. On the antioxidant mechanism of curcumin: classical methods are needed to determine antioxidant mechanism and activity. Org Lett. 2000, 2:2841-3.
35. Jovanovic SV, Boone CW, Steenken S. How curcumin works preferentially with water soluble antioxidants. J Am Chem Soc. 2001, 123:3064-8.
36. Moon Y, Glasgow WC, Eling TE. Curcumin suppresses interleukin 1β-mediated microtonal prostaglandin E syntheses 1 by altering early growth response gene 1 and other signaling pathways. J Pharmacol Exp Ther. 2005, 315:788-95.
37. Chan MM, Huang HI, Fenton MR. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol. 1998, 55:1955-62.